Rubicon Research lifts FY27 operating margin guidance to 24%+

Rubicon Research raised its FY27 operating earnings before interest, tax, depreciation and amortisation (EBITDA) margin guidance to 24%+ after reporting a 25.0% operating EBITDA margin in Q2 FY27, up from 22.9% a year earlier, while revenue from operations increased 39.9% to Rs 576.4 crore.

Why did Rubicon lift FY27 operating-margin guidance?

Rubicon lifted its FY27 operating EBITDA-margin guidance to 24%+ after its Q2 FY27 operating EBITDA margin reached 25.0%, compared with 24.2% in Q1 FY27. Management had raised the FY27 outlook to 23%+ from 22-23% in its Q1 FY27 update. H1 FY27 operating EBITDA margin was 24.6%, against 22.7% in H1 FY26.

The guidance refers to operating EBITDA, excluding recurring other income. Q2 FY27 operating EBITDA increased 52.8% to Rs 144.1 crore from Rs 94.3 crore in Q2 FY26. After Rs 2.3 crore of recurring other income, reported EBITDA was Rs 146.4 crore and its margin was 25.4%, compared with Rs 95 crore and 23.1% a year earlier.

How did Rubicon's Q2 FY27 profit growth compare with revenue growth?

Rubicon's Q2 FY27 profit growth exceeded revenue growth, with revenue up 39.9%, operating EBITDA up 52.8% and profit after tax (PAT) up 67.9%. Revenue increased by Rs 164.4 crore to Rs 576.4 crore, while operating EBITDA rose by Rs 49.8 crore to Rs 144.1 crore. The operating EBITDA margin expanded by 2.1 percentage points from 22.9%.

Profit before tax increased 63.1% to Rs 116.9 crore from Rs 71.7 crore, while PAT rose to Rs 90.4 crore from Rs 53.9 crore. Fully diluted earnings per share rose 56.2% to Rs 5.41. Sequentially, revenue increased from Rs 534.3 crore and PAT from Rs 84.8 crore in Q1 FY27, when the company recorded Rs 3.6 crore of one-off insurance income.

What sustained Rubicon's Q2 margin despite R&D spending?

Rubicon spent Rs 62.4 crore on research and development (R&D) in Q2 FY27, equal to 10.8% of revenue from operations, compared with Rs 46.3 crore, or 11.2%, in Q2 FY26. Operating pre-R&D EBITDA rose to Rs 206.5 crore from Rs 140.6 crore, and the corresponding margin increased to 35.8% from 34.1%.

Gross profit increased 37.3% to Rs 380.8 crore in Q2 FY27, while Rubicon said gross margins were stable sequentially on product revenue. The specialty portfolio contributed 36% of quarterly gross profit, three product approvals were received, and 84% of approved products were commercialised. In H1 FY27, R&D expense was Rs 120.4 crore, or 10.8% of revenue, and the company charged all R&D expense to the profit-and-loss account when incurred.

What cash, capital and regulatory factors should readers track?

Rubicon generated Rs 98.9 crore of net cash flow from operating activities in H1 FY27 after Rs 126.3 crore of working-capital changes and Rs 53.3 crore of income-tax payments. Investing cash outflow was Rs 171.9 crore, including the Rs 175.9 crore Arinna acquisition, Rs 29.1 crore for the New Jersey manufacturing facility excluding lease right-of-use assets, and Rs 65.8 crore of capital expenditure.

Arinna contributed Rs 19.4 crore of Q2 FY27 revenue, compared with Rs 12.8 crore in Q1 FY27, while Rubicon said its EBITDA contribution was not material in either quarter. Net debt was Rs 115.9 crore at 30 September 2026, compared with net cash of Rs 86.6 crore at 31 March 2026. Net working-capital days declined to 117 from 126, although management said the measure would normalise to 125-130 days over coming quarters. Ambernath received five October 2026 observations, while Satara and Pithampur received one and two observations respectively, all described as procedural and unrelated to data integrity.

Conclusion

Rubicon's revised 24%+ FY27 operating EBITDA-margin guidance follows a Q2 in which operating margin reached 25.0% and operating EBITDA grew faster than revenue. The result combined 39.9% revenue growth, a 2.1-percentage-point year-on-year operating-margin increase, and R&D spending held at 10.8% of quarterly revenue.

Next, readers can watch whether Rubicon maintains its 24%+ full-year operating margin as net working-capital days move toward management's stated 125-130-day range and recent approvals are commercialised in the coming quarter. Management is also on track for Rs 500 crore+ of R&D spending over FY26, FY27 and Q1 FY28, having reported Rs 313.9 crore over the first six quarters of that period.